Clinical Trial Update: Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study investigating intrathecal administration of trastuzumab deruxtecan (T-DXd) via Ommaya for HER2-expressing breast cancer with leptomeningeal and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastasis
• Breast Cancer
• Leptomeningeal Metastasis

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING